Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-332

As you know, the dsmb reviews early on when not all patients are recruited. Also the dsmb looks at the drug effect over all patients so far at the review time point. We know overall there is a -2% reduction. Therefore, nothing would be flagged. But we shall see, this is just my
best guess with the information we have been given so far

you don’t get the full picture from the first several patients - especially when you look at all patients together. It le only when you separate out the subgroups that this strange observation comes up

it’s always possible there some other obscure explanation, but I’m just not willing to gamble on that after what happened Monday

for all the holders, I hope I’m wrong